Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma
Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma
复制标题
DOI：
10.1080/10428194.2018.1443331
复制
发表时间：
2018-11-02
影响因子：
2.6
通讯作者：
Jeong, Seong Hyun
中科院分区：
文献类型：
--
作者：
Choi, Yong Won;Park, Joon Seong;Jeong, Seong Hyun
在硼替佐米治疗的多发性骨髓瘤中评估了骨溶解相关蛋白的预测意义。回顾性收集临床病理特征。采用免疫组织化学分析 NF-κ B 配体受体激活剂 (RANKL)、骨保护素 (OPG)、巨噬细胞炎症蛋白 1 α (MIP1 α) 和 dickkopf-1 (DKK1) 的表达。在临床病理特征中，溶骨性病变与硼替佐米治疗的较高反应相关（79% vs. 46%）。 DKK1 高表达与溶骨性病变显着相关 (p = .003)，而 RANKL、OPG 和 MIP1 α 则不然。在高 DKK1 表达中，观察到对硼替佐米的更高反应（84% 对比 44%）。在多变量分析中，DKK1 高表达与硼替佐米的更好反应相关 (p = .005)。 DKK1 高表达的患者在硼替佐米治疗后具有更长的中位无进展生存期 (PFS) 和总生存期 (OS)。在多变量分析中，DKK1 高表达是良好 PFS (p = .027) 和 OS (p = .035) 的独立预后因素。在硼替佐米治疗的多发性骨髓瘤中，DKK1 的表达状态可能是一个有用的预测标记。
The predictive significance of osteolysis-related proteins was evaluated in bortezomib-treated multiple myeloma. The clinicopathological characteristics were collected retrospectively. Immunohistochemistry was performed for analyzing receptor activator of NF-kappa B ligand (RANKL), osteoprotegerin (OPG), macrophage inflammatory protein 1 alpha (MIP1 alpha), and dickkopf-1 (DKK1) expression. Among clinicopatholgical characteristics, osteolytic lesion was associated with higher response to bortezomib treatment (79% vs. 46%). High DKK1 expression was significantly correlated with osteolytic lesion (p = .003), whereas RANKL, OPG, and MIP1 alpha were not. In high DKK1 expression, higher response to bortezomib was observed (84% vs. 44%). In multivariate analysis, high DKK1 expression was associated with better response to bortezomib (p = .005). Patients with high DKK1 expression had longer median progression-free survival (PFS) and overall survival (OS) after bortezomib treatment. In multivariate analysis, high DKK1 expression was an independent prognostic factor of favorable PFS (p = .027) and OS (p = .035). In multiple myeloma treated with bortezomib, expression status of DKK1 may be a useful predictive marker.